BostonGene to Participate in Friends of Cancer Research Meeting
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in the Friends of Cancer Research (Friends) meeting, Advancing the Future of Diagnostics and Regulatory Innovations. The event, which aims to drive innovation in diagnostics and regulatory policy, will be held on February 4 at the Ritz Carlton in Washington, DC.
The meeting will focus on advancing diagnostics and regulatory policy, with sessions addressing evidence generation for cutting-edge technologies like digital pathology and AI, strategies for developing tests for rare biomarkers and future regulatory considerations. New findings from the Digital PATH Project will be presented, which assessed variability in digital pathology platforms using a shared dataset. Key thought leaders will discuss how these innovations can drive precision medicine and improve patient outcomes.
BostonGene’s Chief Scientific Officer, Joe Lennerz, MD, PhD, will participate in the panel session, "Evaluating Digital Pathology and AI in Diagnostics," where he will share insights on the importance of high-quality data, the importance of ground truth and integrating new diagnostics entities and technologies into patient care.
Date: Tuesday, February 4
Time: 10:30 AM – 11:30 AM ET
To schedule a meeting during the event, contact Allie Lewan at [email protected]. For more event details, visit the Friends of Cancer Research website.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
